EW Weekly, November 9, 2018
- Phase 3 clinical trial begins for SkQ1 compound for moderate to severe dry eye
- Phase 3 study for retinal vein occlusion treatment does not meet primary endpoint
- Further results from Phase 2 study for teprotumumab for thyroid eye disease
- Topline results announced in Phase 2 trial for dry eye treatment
- Submit complicated and challenging cases today
Phase 3 clinical trial begins for SkQ1 compound for moderate to severe dry eye
Phase 3 study for retinal vein occlusion treatment does not meet primary endpoint
Further results from Phase 2 study for teprotumumab for thyroid eye disease
Topline results announced in Phase 2 trial for dry eye treatment
Submit complicated and challenging cases today
- One submission per person.
- *New for 2019: The submitter should be the senior author/producer of the video.
- Videos should be no longer than 5 minutes.
- Be certain the video is created as an MPEG or Windows Media file (.wmv). No exceptions will be made.
- A maximum of two PowerPoint slides should be included (one containing title and financial interest, the second with a brief case history).
- If the video will not include narration, please note this in the PowerPoint slide.
Research briefs
- Donor diabetes, a lower screening endothelial cell density, a pseudophakic/aphakic corneal edema (PACE) diagnosis, and operative complications were associated with lower endothelial cell density at 3 years after Descemet's stripping automated endothelial keratoplasty (DSAEK) and may be factors associated with long-term graft outcomes, reported Jonathan Lass, MD, and coresearchers from the Cornea Preservation Time Study. The association of donor diabetes and PACE in recipients with lower 3-year endothelial cell density is worthy of further study, the researchers said. The study included participants who were having DSAEK for Fuchs' dystrophy or pseudophakic/aphakic corneal edema. The study included 40 U.S. clinical sites from the multicenter, double-masked, randomized clinical trial. Study participants randomly received a donor cornea with a preservation time of 0 to 7 days or 8 to 14 days. A total of 1,090 participants were included with 1,330 affected eyes. The previously mentioned factors all were associated with a lower endothelial cell density at 3 years. The results appear in JAMA Ophthalmology.
- Corneal incisions that were 2.20 mm wide were more prone to trauma compared with 2.85 mm incisions during routine cataract surgery, according to a prospective case series from Sunny Li and fellow researchers. There were 50 eyes in both groups in which patients were randomized to receive 2.20 mm or 2.85 mm uniplanar clear corneal incisions. Researchers used optical coherence tomography measurements of incision thickness, length, width, gaping, and several other measurements at baseline and 1, 7, 30, and 90 days postop. With the 2.20 mm incision, the Descemet's membrane detachment rate was greater than 50% (P=.01); those with Descemet's membrane detachments also had increased endothelial cell gaping, slower visual recovery, and increased corneal thickness at the incision site. The 2.20 mm group had greater polymegathism even though there was no difference in mean phaco energy between the groups. At 90 days, the 2.20 mm group had a lower mean endothelial cell density than the 2.85 mm group. There was no significant difference in final visual acuity, gaping, and angles between the groups. The research is published in the Journal of Cataract & Refractive Surgery.
This issue of EyeWorld Weekly Update was edited by Amy Goldenberg and Vanessa Caceres.
EyeWorld Weekly Update (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrators, is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, chief medical editor; Rosa Braga-Mele, MD, cataract editor; Clara Chan, MD, cornea editor; Nathan Radcliffe, MD, glaucoma editor; and Vance Thompson, MD, refractive editor.
For sponsorship opportunities or membership information, contact:
ASCRS•ASOA • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS
Opinions expressed in EyeWorld Weekly Update do not necessarily reflect those of ASCRS•ASOA. Mention of products or services does not constitute an endorsement by ASCRS•ASOA.
Click here to view our Legal Notice.